Bispecific oligonucleotide for the treatment of cns malignancies
CA 2539727 C · Owner: Pollak, Michael N. · Inventors: Pollak, Michael N.; Levitt, Randy J.; Gleave, Martin E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Pharmaceutical compositions for treatment of CNS malignancies comprising a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5 are provided. Methods of using the pharmaceutical composition in the treatment of CNS malignancy via various modes of administration are also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 30, 2004 and granted November 1, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 30, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 30, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.